Climb Bio
CLYM
23 hedge funds and large institutions have $44M invested in Climb Bio in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
5% more funds holding
Funds holding: 22 → 23 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.24% less ownership
Funds ownership: 61.99% → 61.75% (-0.24%)
6% less capital invested
Capital invested by funds: $46.8M → $44M (-$2.85M)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$968K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$96.3K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$7.12K |
| 4 |
State Street
Boston,
Massachusetts
|
+$5.18K |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$2.96K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$1.02M |
| 2 |
TSS
Two Sigma Securities
New York
|
-$40K |
| 3 |
Millennium Management
New York
|
-$18K |
| 4 |
CPIG
Chicago Partners Investment Group
Chicago,
Illinois
|
-$10.3K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.34K |
CLYM Hedge Fund Activity: Q3 2023 in Review
23 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Climb Bio (CLYM) for Q3 2023, worth a combined $44M — down 6.1% from $46.8M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CLYM positions and 1 closed out — a net gain of 1 holder — while 6 added to existing stakes and 8 trimmed.
The largest buyer was BML Capital Management, adding an estimated $968K. The largest seller was Silverarc Capital Management, cutting an estimated $1.02M.
- 23 institutional investors held Climb Bio (CLYM) as of Q3 2023, up from 22 in Q2 2023.
- Funds reported $44M of Climb Bio stock for Q3 2023, down 6.1% quarter-over-quarter.
- 2 funds opened new Climb Bio positions in Q3 2023 and 1 closed out, a net change of +1 holder.
- The largest Climb Bio buyer in Q3 2023 was BML Capital Management, an estimated $968K added.
- The largest Climb Bio seller in Q3 2023 was Silverarc Capital Management, an estimated $1.02M sold.
Based on aggregated 13F filings for Q3 2023.